10-Q quarterly report · filed Nov 12, 2026

CapsoVision, Inc (CV) Q3 2026 10-Q Quarterly Report

Short answer

CapsoVision, Inc (CV) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (up 0.8% year over year) with net income of −$7M.

Q3 2026 key financials · XBRL

Revenue
$4M
+0.8% YoY · −2.1% QoQ
Net income
−$7M
+7.3% YoY · +1.9% QoQ
Operating margin
-207.0%
Gross margin
49.4%
EPS (diluted)
−$0.14
−104.1% YoY · +6.7% QoQ

Source: XBRL data from the CapsoVision, Inc (CV) Q3 2026 10-Q on SEC EDGAR. USD.

CapsoVision, Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $3.568M, up $0.030M, approximately 1% YoY, driven by international CapsoCam Plus sales
  • Gross margin 49% vs 54% YoY, with gross profit $1.764M vs $1.914M
  • International sales strongest, up 8%; U.S. sales weakest, down 1%
  • Operating cash use $21.5M through nine months vs $15.2M YoY, with $21.8M cash at September 30
  • CapsoCam Colon 510(k) submission expected fourth quarter 2026, with substantial doubt about funding operations for 12 months

Risk Factors

  • New regulatory risk: OBBBA Medicaid reforms, including estimated $1 trillion federal spending reduction from 2025 through 2034
  • Most material update: substantial doubt about going concern, cash $21.8 million and additional financing likely needed by early 2027
  • FDA clearance risk: second-generation CapsoCam Colon 510(k) submission planned for fourth quarter 2026, with FDA staff reductions potentially causing delays
  • Competitive risk: Ankon’s FDA-cleared small-bowel AI launched before AI Highlights, potentially reducing market share and revenue opportunities
  • Concentration risk: Aureliance represented 11% of nine-month revenue and 23% of accounts receivable at September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CapsoVision, Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.